Values Added Financial LLC Sells 202 Shares of Stryker Co. (NYSE:SYK)

Values Added Financial LLC lessened its position in shares of Stryker Co. (NYSE:SYK) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,553 shares of the medical technology company’s stock after selling 202 shares during the quarter. Values Added Financial LLC’s holdings in Stryker were worth $465,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SYK. Fairfield Bush & CO. purchased a new stake in Stryker during the first quarter valued at $131,000. Dimensional Fund Advisors LP increased its position in Stryker by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock worth $180,182,000 after buying an additional 9,026 shares in the last quarter. Prudential PLC purchased a new stake in Stryker in the first quarter worth about $1,444,000. Sequoia Financial Advisors LLC increased its position in Stryker by 21.6% in the first quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock worth $817,000 after buying an additional 543 shares in the last quarter. Finally, Zions Bancorporation N.A. increased its position in Stryker by 9.2% in the first quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock worth $839,000 after buying an additional 265 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.2 %

SYK opened at $357.87 on Friday. The stock’s fifty day moving average is $343.42 and its two-hundred day moving average is $305.60. The company has a market capitalization of $136.16 billion, a P/E ratio of 43.38, a PEG ratio of 2.92 and a beta of 0.89. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the business posted $3.00 EPS. Stryker’s quarterly revenue was up 11.8% on a year-over-year basis. Analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s dividend payout ratio is presently 38.79%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SYK. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research report on Wednesday, January 31st. Wells Fargo & Company increased their price target on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Roth Mkm raised their price objective on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and raised their price objective for the company from $315.00 to $360.00 in a research note on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $331.52.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,109 shares of company stock worth $72,845,768. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.